IPD Stock Overview
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ImpediMed Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.099 |
| 52 Week High | AU$0.23 |
| 52 Week Low | AU$0.076 |
| Beta | 2.93 |
| 1 Month Change | 1.02% |
| 3 Month Change | -26.67% |
| 1 Year Change | -17.50% |
| 3 Year Change | -20.80% |
| 5 Year Change | -56.48% |
| Change since IPO | -46.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| IPD | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 8.8% | -1.7% | -3.1% |
| 1Y | -17.5% | 14.3% | 4.0% |
Return vs Industry: IPD underperformed the Australian Medical Equipment industry which returned 14.3% over the past year.
Return vs Market: IPD underperformed the Australian Market which returned 4% over the past year.
Price Volatility
| IPD volatility | |
|---|---|
| IPD Average Weekly Movement | 10.3% |
| Medical Equipment Industry Average Movement | 10.2% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: IPD's share price has been volatile over the past 3 months.
Volatility Over Time: IPD's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 76 | Parmjot Bains | www.impedimed.com |
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics.
ImpediMed Limited Fundamentals Summary
| IPD fundamental statistics | |
|---|---|
| Market cap | AU$192.19m |
| Earnings (TTM) | -AU$19.50m |
| Revenue (TTM) | AU$10.47m |
18.4x
P/S Ratio-9.9x
P/E RatioIs IPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPD income statement (TTM) | |
|---|---|
| Revenue | AU$10.47m |
| Cost of Revenue | AU$1.37m |
| Gross Profit | AU$9.11m |
| Other Expenses | AU$28.60m |
| Earnings | -AU$19.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0096 |
| Gross Margin | 86.95% |
| Net Profit Margin | -186.16% |
| Debt/Equity Ratio | 0% |
How did IPD perform over the long term?
See historical performance and comparison